It is confirmed that ESCC exhibits significant amino acid metabolic dysregulation, with arginine related metabolic pathways being significantly enriched, and NO can serve as a potential non-invasive biomarker for distinguishing ESCC.
Abstract
Objective Due to the lack of specific biomarkers, patients with esophageal cancer are often diagnosed at an advanced stage, resulting in poor treatment outcomes. This study aims to identify potential diagnostic and therapeutic biomarkers for esophageal squamous cell carcinoma (ESCC) through metabolomics and to elucidate their mechanisms of action. Methods Untargeted metabolomics was employed to analyze ESCC tissue samples and matched normal esophageal tissue samples. Differentially expressed metabolites were identified using multivariate statistical analysis. MetaboAnalyst 6.0 software was used for pathway analysis. Key molecules were validated via immunohistochemistry (IHC) and Western blot (WB), and their functions were assessed through cellular functional assays. Results A total of 2,850 metabolites were identified, among which 939 were differentially regulated, including 575 upregulated and 364 downregulated metabolites. Pathway enrichment analysis revealed that these differentially expressed metabolites were predominantly enriched in amino acid metabolism-related pathways, Mechanistically, activation of the HIF-1α–iNOS–NO signaling axis drove arginine metabolic reprogramming, leading to profound metabolic disturbances that ultimately enhanced the migratory and invasive capacities of ESCC cells. Conclusion This study confirms that ESCC exhibits significant amino acid metabolic dysregulation, with arginine related metabolic pathways being significantly enriched. This disruption in arginine metabolism may be caused by hypoxia, which activates the iNOS-NO signaling axis mediated by HIF-1α, thereby promoting the migratory and invasive capabilities of ESCC. Finally, the study confirmed that NO can serve as a potential non-invasive biomarker for distinguishing ESCC.
It is demonstrated that metformin significantly reduced ESCC cells' viability, proliferation, migration, and invasion, while enhancing apoptosis, which provides new insights into the therapeutic potential of metformin in the treatment of ESCC.
Huayu Luo, Tao Shen, Jing Zhang et al.· Recent Patents on Anti-Cance...· 0 citations
The risk score established by m6A and autophagy can be used to predict prognosis and susceptibility to anticancer drugs in patients with ovarian cancer.
Y. Chen, X. Yu, W. Chu et al.· medRxiv· 0 citations
ADH6 and BDH1 were identified as significantly downregulated genes associated with patient survival in CRC and demonstrated promising tissue-based diagnostic discrimination between tumor and normal samples.
Fatemeh Kaviani, Samaneh Dalali, Mohammad Mahdevar et al.· Current Genetic Medicine Rep...· 0 citations
Bioinformatics analyses suggest that EPHX2 may participate in metabolic and tumor progression-related regulatory networks and may serve as a prognostic biomarker in LUAD.
The findings lay the groundwork for precision oncology paradigms, facilitating the translational trajectory of these targets to optimize clinical prognosis, and underscores the potential of UMARGs in advancing HCC treatment strategies and improving patient outcomes.
This study attempted to investigate the pathogenic mechanism of endometritis and discover potential biomarkers for diagnosing and treating endometritis, finding hub genes (ALDH3A2 and ACSS3) play critical roles in the pathogenesis of endometritis by interacting with different metabolites.